Humacyte, Inc. (HUMA) – What Are Investment Firms Thinking About This Stock?

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $4.96.

A number of research firms have recently issued reports on HUMA. Williams Trading set a $1.00 target price on Humacyte in a report on Friday, October 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a report on Friday, October 16th. Barclays upgraded shares of Humacyte to a “hold” rating in a research report on Wednesday, October 7th. Finally, BTIG Research reissued a “buy” rating and issued a $2.00 price objective on shares of Humacyte in a research note on Wednesday, August 12th.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in shares of Humacyte during the second quarter worth about $4,700,000. BlackRock Inc. acquired a new stake in Humacyte in the second quarter valued at about $3,777,000. GSA Capital Partners LLP acquired a new stake in Humacyte in the second quarter valued at about $785,000. HBK Investments L P acquired a new stake in Humacyte in the second quarter valued at about $617,000. Finally, Wealth Effects LLC purchased a new stake in Humacyte in the 2nd quarter valued at approximately $542,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

Shares of HUMA opened at $0.41 on Friday. The company’s 50 day simple moving average is $0.52 and its 200-day simple moving average is $0.81. The firm has a market cap of $114.23 million, a PE ratio of -0.84 and a beta of 2.44. Humacyte has a 12-month low of $0.34 and a 12-month high of $1.68. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The business had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.04 million. As a group, equities analysts predict that Humacyte will post -0.40 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.